Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020
Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and…
-
-
Ferring Pharmaceuticals to Share New Reproductive Medicine Data at ASRM 2020 Scientific Congress & Expo
Ferring will deliver 11 presentations at the virtual congress; including six oral presentations The new data being presented further underscores…
-
Ferring US issues Voluntary Nationwide Recall of DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, STIMATE® Nasal Spray 1.5 mg/mL Due to Superpotency
FOR IMMEDIATE RELEASE – Parsippany, NJ – August 5, 2020– Ferring Pharmaceuticals US is voluntarily recalling all lots on the…
-
ORTIKOS™ (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S.
ORTIKOS is available in one convenient pill in two dosage strengths (9mg, 6mg) for the treatment of mild to moderate…
-
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease
Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the U.S. Co-promotion strengthens commitment to patients…
-
Brent Ragans named President of Ferring US
Ragans is now responsible for Ferring US commercial, manufacturing and development operations Ragans joined Ferring, a world leader in reproductive…
-
New Clinical Data Published on Menopur® (menotropins for injection) in a Predicted High Responder Population
MEGASET-HR (high responder) study met its primary non-inferiority endpoint, with Menopur-treated patients experiencing a 35.5% ongoing pregnancy rate (OPR) per…
-
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3…
-
New Initiative Provides Personalized Fertility Consultation in the Comfort of Your Home
Fertility House Calls service offered to residents of Greater Denver metro area as part of a pilot program Personalized service…
-
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months
The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at…